• 1
    Schett G, Hayer S, Zwerina J, Redlich K, Smolen JS. Mechanisms of disease: the link between RANKL and arthritic bone disease. Nat Clin Pract Rheumatol 2005; 1: 4754.
  • 2
    Deodhar AA, Woolf AD. Bone mass measurement and bone metabolism in rheumatoid arthritis: a review. Br J Rheumatol 1996; 35: 30922.
  • 3
    Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004; 292: 4905.
  • 4
    Sarzi-Puttini P, Fiorini T, Panni B, Turiel M, Cazzola M, Atzeni F. Correlation of the score for subjective pain with physical disability, clinical and radiographic scores in recent onset rheumatoid arthritis. BMC Musculoskelet Disord 2002; 3: 18.
  • 5
    Sharp JT, Young DY, Bluhm GB, Brook A, Brower AC, Corbett M, et al. How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? Arthritis Rheum 1985; 28: 132635.
  • 6
    Van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 2000; 27: 2613.
  • 7
    Deodhar AA, Brabyn J, Pande I, Scott DL, Woolf AD. Hand bone densitometry in rheumatoid arthritis, a five year longitudinal study: an outcome measure and a prognostic marker. Ann Rheum Dis 2003; 62: 76770.
  • 8
    Deodhar AA, Brabyn J, Jones PW, Davis MJ, Woolf AD. Measurement of hand bone mineral content by dual energy x-ray absorptiometry: development of the method, and its application in normal volunteers and in patients with rheumatoid arthritis. Ann Rheum Dis 1994; 53: 68590.
  • 9
    Rosholm A, Hyldstrup L, Backsgaard L, Grunkin M, Thodberg HH. Estimation of bone mineral density by digital x-ray radiogrammetry: theoretical background and clinical testing. Osteoporos Int 2001; 12: 9619.
  • 10
    Haugeberg G, Conaghan PG, Quinn M, Emery P. Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study. Ann Rheum Dis 2009; 68: 1898901.
  • 11
    Hoff M, Kvien TK, Kalvesten J, Elden A, Haugeberg G. Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: explorative analyses from the PREMIER study. Ann Rheum Dis 2009; 68: 11716.
  • 12
    Kearns AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factor κ B ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 2008; 29: 15592.
  • 13
    Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008; 58: 1299309.
  • 14
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31524.
  • 15
    Lu Y, Mathur AK, Blunt BA, Gluer CC, Will AS, Fuerst TP, et al. Dual x-ray absorptiometry quality control: comparison of visual examination and process-control charts. J Bone Miner Res 1996; 11: 62637.
  • 16
    Lassere M, McQueen F, Ostergaard M, Conaghan P, Shnier R, Peterfy C, et al. OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Exercise 3: an international multicenter reliability study using the RA-MRI score. J Rheumatol 2003; 30: 136675.
  • 17
    McQueen F, Lassere M, Edmonds J, Conaghan P, Peterfy C, Bird P, et al. OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies: summary of OMERACT 6 MR imaging module [review]. J Rheumatol 2003; 30: 138792.
  • 18
    Peterfy C, Edmonds J, Lassere M, Conaghan P, Ostergaard M, McQueen F, et al. OMERACT Rheumatoid Arthritis MRI Studies Module [review]. J Rheumatol 2003; 30: 13645.